Bignotti E, Simeon V, Ardighieri L, Kuhn E, et al. TP53 mutations and survival in ovarian carcinoma patients receiving first-line chemotherapy plus bevacizumab: Results of the MITO16A/MaNGO OV-2 study. Int J Cancer 2024 Oct 16. doi: 10.1002/ijc.35203.
PMID: 39415516